SCHEDULE: RA Capital Discloses 7.5% Stake in LB Pharmaceuticals

RA Capital Management and its affiliates have reported a 7.5% beneficial ownership stake in LB Pharmaceuticals Inc., totaling 1,675,000 shares.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have disclosed beneficial ownership of common stock in LB Pharmaceuticals Inc.
• The aggregate amount beneficially owned by each Reporting Person is 1,675,000 shares.
• This represents 7.5% of LB Pharmaceuticals Inc.'s common stock outstanding.
• The percentage is based on 22,442,989 shares of common stock outstanding as of September 12, 2025, as disclosed in the Issuer's final prospectus dated September 10, 2025.
• The shares are held by RA Capital Healthcare Fund, L.P., with RA Capital Management, L.P. serving as the investment adviser and having shared voting and dispositive power over the shares.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 8

Explanation: The disclosure of a 7.5% beneficial ownership by RA Capital Management, a prominent healthcare-focused investment firm, is a strong positive signal. It indicates significant institutional confidence in LB Pharmaceuticals Inc.'s value and future prospects.

Positives

• A prominent healthcare-focused investment firm, RA Capital Management, has taken a significant 7.5% stake in LB Pharmaceuticals Inc.
• This indicates a vote of confidence from a sophisticated institutional investor in the company's prospects.
• The investment by RA Capital, known for its expertise in the life sciences sector, could attract further investor interest and validate the company's potential.

Risks

• The filing itself does not detail specific risks related to LB Pharmaceuticals Inc.'s operations or financial health, as it is a disclosure of ownership.

Future Outlook

The filing does not provide any forward-looking statements or guidance from LB Pharmaceuticals Inc. or the Reporting Persons regarding the company's future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

RA Capital Management is a well-known investment firm specializing in the healthcare and life sciences sectors. Their significant stake in LB Pharmaceuticals Inc. suggests a belief in the company's potential within the competitive pharmaceutical industry, potentially signaling future growth or development milestones. Such an investment by a specialized fund can often be seen as a positive indicator for a smaller or developing pharmaceutical company.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence the company's stock price positively.
• Management: The presence of a large, specialized investor like RA Capital could lead to increased scrutiny or strategic input, though the filing states the acquisition is not for influencing control.

Next Steps

• LB Pharmaceuticals Inc. will continue its operations and strategic initiatives.
• RA Capital Management, L.P. will continue to monitor its investment in LB Pharmaceuticals Inc.

Key Dates

Recommendation

The disclosure of a 7.5% stake by RA Capital Management, a highly respected and specialized healthcare investment firm, signals strong institutional confidence in LB Pharmaceuticals Inc. This significant investment by a sophisticated player often precedes positive developments or indicates a belief in undervalued assets, making it a compelling "buy" signal for investors.

Keywords

LB Pharmaceuticals, RA Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Healthcare Fund, Biotechnology, Pharmaceuticals, Equity Stake